Valeant Pharmaceuticals names new board member
Mr Lonner was appointed to fill a vacant board position with a term that expires in 2011. His election brings the company’s board to eight members. Mr Lonner
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.
The collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from Uppsala University, said Beactica. Under the terms of the